The second edition of Gestational Trophoblastic Disease: Diagnostic and Molecular Genetic Pathology, edited by Pei Hui, MD, PhD, professor of pathology and of obstetrics, gynecology & reproductive sciences at Yale School of Medicine, has been published by Springer. The new edition offers substantial updates to this rapidly evolving field.
Since the first edition, gestational trophoblastic disease (GTD) has advanced to the forefront of precision medicine, with significant improvements in diagnostic accuracy and patient management driven by innovations in pathology and clinical therapy. This new edition integrates these developments, highlighting key themes such as the molecular pathogenesis of GTD, updated WHO classifications and disease entities, refined diagnostic criteria, emerging immunohistochemical biomarkers, precision genotyping, and novel clinical interventions, including cutting-edge immunotherapies for high-risk gestational trophoblastic neoplasms.
Hui, a pioneer in the clinical validation and application of ancillary studies in the diagnosis and subclassification of GTD, is founder and director of the Center for the Precision Medicine of Trophoblastic Disease at Yale. The center offers consultation services to pathologists nationally and internationally, and its experts are committed to advancing precision medicine by harnessing the latest molecular discoveries and novel treatment options for GTD.
One of the most notable enhancements to the book’s second edition is the expanded visual content, featuring a rich collection of images for each GTD entity, meticulously curated from consultation files spanning several decades. These resources are designed to improve recognition and retention of critical diagnostic features, immersing readers in case-based learning that reinforces proficiency and deepens understanding. Several new chapters have been added, including one on non-gestational trophoblastic tumors of germ cell or somatic origin. Updated guidelines for risk assessment and management are integrated throughout, reflecting the latest research, clinical trials, and advances in personalized patient care.